

Table 1.23
U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2013^a
By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
All Sites									
Males	6,630,144	18,977	42,515	89,810	160,506	352,035	920,363	1,777,405	3,268,534
Females	7,510,110	17,057	36,959	90,895	235,457	635,354	1,378,596	1,900,156	3,215,637
Oral Cavity & Pharynx									
Males	200,280	28	471	1,653	3,431	13,626	48,036	65,705	67,330
Females	100,402	96	546	1,517	3,868	8,513	19,303	25,928	40,633
Esophagus									
Males	28,878	0	0	6	138	1,080	4,812	10,234	12,607
Females	7,979	0	0	22	34	189	1,353	2,058	4,324
Stomach									
Males	45,442	0	40	177	555	2,588	7,433	12,737	21,912
Females	34,401	0	27	231	757	2,445	4,965	7,644	18,332
Colon & Rectum									
Males	585,136	11	94	1,316	6,064	26,227	85,943	144,658	320,823
Females	592,420	0	230	1,444	6,369	23,982	73,478	117,870	369,046
Liver & Intrahep									
Males	39,334	612	484	604	641	1,590	11,144	15,911	8,350
Females	15,620	413	570	434	455	1,044	3,383	4,681	4,640
Pancreas									
Males	24,363	34	23	153	365	1,584	5,088	7,791	9,324
Females	25,257	0	12	288	536	1,593	4,671	7,156	11,001
Larynx									
Males	71,488	0	0	89	292	1,713	10,143	21,196	38,055
Females	17,593	0	0	28	144	847	3,543	5,051	7,979
Lung & Bronchus									
Males	186,030	34	75	517	1,120	4,955	23,975	55,413	99,941
Females	229,677	34	104	399	1,489	6,572	31,088	61,774	128,218
Melanoma of the Skin									
Males	509,094	56	696	4,938	17,619	45,039	99,914	144,398	196,432
Females	525,366	113	834	10,310	34,836	72,511	121,614	127,402	157,747

^a U.S. 2013 cancer prevalence counts are based on 2013 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2013 U.S. population estimates based on the average of 2012 and 2013 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^b Cases diagnosed more than 38 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 1.23 - continued
 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2013^a
 By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
Breast									
Males	15,781	0	0	11	115	703	1,911	4,527	8,514
Females	3,053,450	11	47	2,984	36,611	211,630	567,039	845,870	1,389,258
Cervix									
Females	248,920	0	68	1,821	14,820	40,574	59,368	60,139	72,130
Corpus & Uterus, NOS									
Females	635,437	11	23	629	6,040	25,247	93,125	182,278	328,082
Ovary ^d									
Females	195,767	105	1,012	3,796	6,939	18,071	41,987	52,895	70,961
Prostate									
Males	2,850,139	34	46	104	343	18,486	237,236	815,954	1,777,936
Urinary Bladder									
Males	438,068	68	105	551	2,315	9,819	42,325	105,894	276,992
Females	149,358	68	34	241	968	3,908	13,820	31,806	98,514
Kidney & Renal Pelvis									
Males	234,706	1,375	2,285	2,963	5,082	19,921	46,181	68,291	88,610
Females	159,630	1,455	2,581	3,065	5,082	12,617	28,144	40,702	65,983
Hodgkin Lymphoma									
Males	100,096	203	2,405	9,526	16,482	23,489	23,526	16,032	8,431
Females	93,449	34	2,104	9,344	16,640	22,518	21,509	13,067	8,232
Non-Hodgkin Lymphoma									
Males	300,417	927	3,738	8,182	14,080	29,312	57,496	77,491	109,191
Females	269,119	452	1,681	4,846	9,401	21,417	43,880	66,307	121,135
Myeloma									
Males	51,465	0	6	110	539	3,457	9,101	16,940	21,313
Females	44,223	0	0	45	377	2,237	7,664	12,935	20,965
Leukemia									
Males	189,019	6,519	13,341	13,964	12,067	15,409	26,626	39,493	61,600
Females	144,956	6,039	10,458	12,073	11,027	11,191	17,766	26,051	50,352
Acute Lymphocytic Leuk									
Males	42,395	5,394	11,202	10,799	6,965	4,601	1,951	925	559
Females	35,460	5,139	8,796	8,782	6,216	3,365	1,545	1,069	549

^a U.S. 2013 cancer prevalence counts are based on 2013 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2013 U.S. population estimates based on the average of 2012 and 2013 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the First Malignant Primary Only for a person.

^b Cases diagnosed more than 38 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.